Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct-Dec;21(4):1470320320966445.
doi: 10.1177/1470320320966445.

The role of renin-angiotensin system in patients with left ventricular assist devices

Affiliations
Review

The role of renin-angiotensin system in patients with left ventricular assist devices

Alexandros Briasoulis et al. J Renin Angiotensin Aldosterone Syst. 2020 Oct-Dec.

Abstract

End-stage heart failure is a condition in which the up-regulation of the systemic and local renin-angiotensin-aldosterone system (RAAS) leads to end-organ damage and is largely irreversible despite optimal medication. Left ventricular assist devices (LVADs) can downregulate RAAS activation by unloading the left ventricle and increasing the cardiac output translating into a better end-organ perfusion improving survival. However, the absence of pulsatility brought about by continuous-flow devices may variably trigger RAAS activation depending on left ventricular (LV) intrinsic contractility, the design and speed of the pump device. Moreover, the concept of myocardial recovery is being tested in clinical trials and in this setting LVAD support combined with intense RAAS inhibition can promote recovery and ensure maintenance of LV function after explantation. Blood pressure control on LVAD recipients is key to avoiding complications as gastrointestinal bleeding, pump thrombosis and stroke. Furthermore, emerging data highlight the role of RAAS antagonists as prevention of arteriovenous malformations that lead to gastrointestinal bleeds. Future studies should focus on the role of angiotensin receptor inhibitors in preventing myocardial fibrosis in patients with LVADs and examine in greater details the target blood pressure for these patients.

Keywords: Heart failure; LVAD; hypertension; renin angiotensin system.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
The role of renin-angiotensin-aldosterone system in advanced heart failure and support with left ventricular assist devices.
Figure 2.
Figure 2.
The pressure-volume loop with and without a left ventricular assist device (a) and the relationship between blood flow and rotor speed or head pressure (b). LV: left ventricle; ESPVR: end systolic pressure volume relationship; EDPVR: end diastolic pressure volume relationship; LVAD: left ventricle assist device; Head pressure: pressure differential between LV and aorta.

Similar articles

Cited by

References

    1. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol 2011; 8: 30–41. - PMC - PubMed
    1. Cook C, Cole G, Asaria P, et al. The annual global economic burden of heart failure. Int J Cardiol 2014; 171: 368–376. - PubMed
    1. Kalogeropoulos AP, Samman-Tahhan A, Hedley JS, et al. Progression to stage D heart failure among outpatients with stage C heart failure and reduced ejection fraction. JACC Hear Fail 2017; 5: 528–537. - PubMed
    1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016; 37: 2129–2200. - PubMed
    1. Terzi A. Mechanical circulatory support: 60 years of evolving knowledge. Int J Artif Organs 2019; 42: 215–225. - PubMed

LinkOut - more resources